Pulse Biosciences, Inc. (PLSE)
NASDAQ: PLSE · Real-Time Price · USD
44.84
-1.52 (-3.28%)
At close: Nov 17, 2026, 4:00 PM EST
46.00
+1.16 (2.59%)
After-hours: Nov 17, 2026, 7:30 PM EST
← View all transcripts

Stifel 2026 Healthcare Conference 2026

Nov 12, 2026

Summary

nsPFA feasibility results showed 96% freedom from AF off drugs at 12 months, and the pivotal IDE completed enrollment in October. Management expects CE mark in H2 2027 and U.S. approval early in 2028, while advancing persistent AF and other indications.

Rick Wise
Analyst, Stifel

Alrighty. My name is Rick Wise, as I've mentioned before today. I'm truly thrilled, and it is my pleasure to welcome Pulse Biosciences. To my right here, Paul LaViolette, Pulse Bio's Chief Executive and Co-Chairman. Jon Skinner, Chief Financial Officer, is in the audience. Thank you both for being here. I've had the pleasure, I have to brag about something, of knowing Paul since 1989 when he was head of C. R. Bard's vascular division. Who would have thought in 1989, Paul, we'd be sitting here all these years later with your—

Paul LaViolette
CEO and Co-Chairman, Pulse Biosciences

Exactly.

Rick Wise
Analyst, Stifel

—most exciting story to date. Is that a good opening?

Paul LaViolette
CEO and Co-Chairman, Pulse Biosciences

That is a perfect opening, and I'll take it from there. Thank you, Rick. It's an honor to be on the stage with you. I do think the history, as we've walked through the growth of interventional medicine, is relevant. Maybe I left the clicker over here. I'll comment just briefly on Pulse Biosciences. We'll make some forward-looking statements today, so here's our disclaimer. Let me just talk about our mission and what drove me to the company after multiple decades, starting in med tech in 1980 and having been at this now for over 45 years, is a unique combination of characteristics.

The novelty of the technology this company possesses, the ubiquitous nature of ablation, and how a novel energy can be an enabler to the conversion of so many procedures to a less invasive and more patient-friendly alternative with all the benefits of health economics, all the benefits of improved outcomes. There's so much here to unpack with Pulse Biosciences. It is, in fact, that which had me join the company two years ago as a CEO, and it's been a remarkable run in many ways because the company has become manifest in the last year with clinical data, clinical trials, product development advances on multiple fronts, and that's what we'll spend time talking about today. The mission of Pulse Biosciences is very clearly focused on the fulfillment of the potential of nsPFA.

We've seen, and we'll talk more about pulsed field ablation and this new dynamic of pulsed electric field ablation. But nsPFA is a truly different form of energy, and Pulse Biosciences is uniquely positioned to be the first and the best, and maybe the only practitioner of this energy form. What is amazing to me is that we've seen energies come along over time and take over markets. We now, I think, have the potential to see nsPFA take over multiple markets, and that's what we find so intriguing as a business prospect. It is an energy that delivers a unique mechanism of action. It's an energy that we are rigorously developing with product development and clinical milestones, and one where in every direction we turn, we see significant potential advantage for patients. As I mentioned, I have a lot of experience in the medical device field.

I'm joined by a great senior executive team, maybe the most notable of which are Darrin Uecker and Liane Teplitsky, Chief Technology and Operating Officers respectively. The three of us have a lot of experience developing and commercializing significant technologies, and we really feel well-prepared to seize on this opportunity. We were joined earlier this year in a full-time status by David Kenigsberg. He's a key opinion leader electrophysiologist. He became full-time Chief Medical Officer. We'll talk about the clinical trial he just helped to orchestrate, but we've now completely enrolled our pivotal IDE in atrial fibrillation, and no better evidence of his impact on the company than that success. Bob Duggan spearheads a Board of Directors that is extremely experienced. Bob has a very long track record in life sciences, drug development, med tech development.

He's been at this for over 50 years, remarkably successful as an entrepreneur, as an investor, and we're privileged to have his support and involvement literally on a daily basis. Over the last year, we've substantially increased our financial capabilities. We strengthened our balance sheet, ending last quarter with $189 million in cash and marketable securities. Our goal is to exit the year closer to $200 million. We feel very strongly about that. We've been quite opportunistic as the stock price has grown. We've added capital in a very minimally dilutive way to support our core strategies, which are highlighted by our focus on atrial fibrillation, running those studies, generating that data, advancing our product pipeline, now beginning to invest incrementally in manufacturing startups so that we can get a head start on preparation for market launch at scale in 2028.

We are going to continue to expand our IDE activity with new indications and an expansion into the persistent population, which we'll talk about, and do everything necessary to support this platform's readiness to take on and be disruptive in significant markets. Just a minute on the technology itself. Energy is used to ablate tissue, to eliminate unwanted tissues in the body, and to restore normal bodily function. Radiofrequency or thermal ablation is used millions of times a month, and it is destructive. It destroys the tissue you're targeting. It also increases the risk of destroying adjacent tissues and producing unwanted adverse effects. There's no question it's beneficial, but there's also no question about the desirability of changing away from that thermal modality. Then, of course, we observe first-generation microsecond PFA come along.

Nothing more notable than the Boston Scientific FARAPULSE launch, which, of course, upended the atrial fibrillation market. You do need to think about this as a first-generation technology. It is microsecond PFA that is relatively early stage, relatively slow, relatively inefficient form of delivering a pulsed electric field. It operates ever so close to the thermal range. If you deliver too much microsecond pulsing in a given space, you will create a thermal effect. We have seen that in the marketplace, leading to product recalls and changes in labeling and technique. Nanosecond PFA, where we operate, is not 10 x faster, it is not 100 x faster, it is 1,000-fold faster in terms of pulse duration, and we add to that a meaningful, a multiple increase in the energy that we deliver in terms of voltage amplitude.

As a result of that unique combination, we produce a different form of energy that produces a different mechanism of action in the tissue, and we are starting to see the clinical outcome of that. Those unique properties combine to create enormous invention potential. This is one of the slides we have had to update most frequently because our issued patents have grown by more than 10% this year with an incremental 30 issued patents. This is one of the most comprehensively protected technology platforms one will find. We have intellectual property on how to generate these nanopulse waveforms. We have methods applications. For instance, the application of nsPFA to cardiac tissue is patented. We have intellectual property on the catheter design that is so broad that it is not even limited to the use of nsPFA.

Our catheter has many advantages, and one cannot reproduce that catheter design or function regardless of whether you are using nsPFA or microsecond PFA or refrigeration, for all of that matter. Now, let us talk about the market that we are going after principally, and that is the atrial fibrillation market. I think everybody is aware that AFib is the most common atrial arrhythmia in man. You see from this blue chart here, there are nearly 2 million new diagnoses per year and estimated more than 10 million prevalence in the United States. Now, this is not a benign affliction.

Patients with AFib have a sixfold increase in stroke risk, and it is not only a condition that causes quality of life impairment, but holds fundamental outcomes risks that no patient wants to live with. The solutions for which have historically been some combination of anticoagulation and antiarrhythmic drugs, which also produce significant side effects. Patients are in a bind. What is really driving this market is, number one, increased incidence in the population. We are aging less gracefully. Patients have higher body weight. They have hypertension that leads to stresses on the cardiac structure, which leads to atrial stretching, which causes atrial fibrillation. So we are actually living a life that causes this disease to happen more often.

In addition to that, we're wearing iWatches, which allow us to diagnose it, and we can prescribe to a wearable ambulatory cardiac monitoring patch that will definitively diagnose AFib without even having to see a medical professional. This market is very large, it's growing very rapidly, and it's projected to more than double over the next five to seven years. That has led to a $4 billion ablation market, which is about half of the overall EP market. Again, that number will approach more like $10 billion in the early 2030s. This is a very significant market that has driven growth because of the movement of care for these patients closer and closer to ablation as a frontline indication.

As we saw with the first PFA launch two years ago from Boston Scientific, if you can drop a catheter into that workflow, it will move through and wipe out the prior generation of energy, which PFA did with RF, and we fully expect nsPFA has the potential, and we will demonstrate the outcomes necessary to believe that this will do the same. Next-generation PFA will do the same to first-generation PFA as first-generation PFA did to RF. We feel very good about that prospect, and our job now is to really deliver on that promise with a development and clinical program that really is built upon, I would say, these four pillars. What does nsPFA deliver to cardiac tissue and in the hands of an electrophysiologist that fundamentally has disruptive potential for the AFib market? Number one, we simply make better lesions.

This is a challenge of delivering energy into atrial tissue and delivering transmural ablations that isolate electrical signals, do it quickly, do it reliably, do it consistently, do it safely, and have that ultimately translate into improved outcomes. We're seeing that unquestionably, and we'll talk about the data in support of my comments. This is about speed. How do you take care of 2 million patients a year? You need throughput. You need outcomes that deliver a single-intervention effectiveness, and we're seeing that. While our pivotal outcomes data look fantastic from our feasibility study and will be validated with our IDE results, there's incontrovertible evidence of the workflow advantages this device has in the lab, in the hands of the electrophysiologist. Our ablation times are faster. The number of ablations we have to deliver are fewer.

You put that together, you create much, much reduced ablation time, lower left atrial dwell time, faster overall procedure time, much better throughput. You can do two or three more cases per room per day, and each of those cases brings $23,000 of revenue for that service line. This is a way to treat a larger patient population, ease the work life of electrophysiologists, increase profitability for the healthcare system, and it's a win-win-win combination based on nsPFA. You take that same set of advantages and imagine this, let's say the growth, the pressure relief valve of capacity in the system is the development of ASCs to supplement hospitals. What does an ASC want? Reliable procedure time, low anesthesia level, high safety, predictable procedures for scheduling benefit, and ultimately low anesthesia levels so that patients recover quickly from the procedure and can be discharged that same afternoon.

That's exactly what this catheter system offers, and the efficacy is unprecedented, and we will spend a minute talking about that now. Most companies do a feasibility study of 10 or 15 patients, and then they try to get an IDE started. We did a feasibility study 10 x larger than that, because we really wanted to understand exactly how this catheter functioned. The results have been in a class entirely by themselves. Here you see that the average number of applications of energy is only 12. 12 five-second applications of this energy, and you have completed the lesion set necessary to address paroxysmal AF. What did that lead to? For the first time, we have seen long-term outcomes, 100% clinical success, which is freedom from atrial fibrillation, off drugs, 100% success at six months, and 96% at 12 months.

Now, to put that in perspective, if you treat 100 patients and they have this level of success, that means only four out of 100 patients will fail and require a second intervention. If you then say, "Well, what's the standard of care today?" It's more like 25 out of 100 failing. To reduce from 25 to four or five, you are reducing the failure rate of a contemporary first-line intervention by 80%. That is clinical outcomes gain that is rarely seen in the interventional space. If you look at our even broader measure of freedom from all atrial arrhythmias, be it fibrillation, flutter, or tachycardia, you see again 90% at 12 months. These are levels of success that have not been equaled by any other technology platform.

We are following this patient cohort, and we will aim to report out on 100 patients at a year in Q1 at one of the AFib conferences. Let's look at what we are doing next. We parlayed that extraordinary feasibility data into an IDE. That IDE was approved early this year. We treated our first patient in April and our last patient in October. Under 180 days to enroll our pivotal study, which is also unprecedented, certainly for an early-stage company, and exemplifies the physician enthusiasm behind this platform. The combination of high feasibility data, high expectations for clinical outcomes here, rapid enrollment, leading to six-month data in-house for us by April, and all of that supporting a modular submission where the clinical module can be filed for the FDA in early Q3 and start the clock for FDA approval approximately six months after that.

We are turning our sights then toward a persistent study. We are planning to file a persistent IDE in the fourth quarter and start that study early in the new year. In parallel with that, plan to do additional clinical trials in Europe to expand our learning of how this catheter performs so well. The next generation of the catheter will set another standard. We have a large footprint regional ablation tool today, as evidenced by the device on the left. We are going to pair that with a focal ablation, a large footprint focal ablation device that will be in the center of the device.

You put those two devices in the same catheter and allow a switching mechanism so the physician can move from a regional footprint ablation to a focal targeted ablation and allow work efficiently in the pulmonary veins or then movement anywhere around the left or the right atrium to produce extra-PV lines and treat a much broader patient population with a single catheter workflow. We think that's going to be incrementally disruptive to the market. Importantly, our company is focused not just on AFib, but we have a couple of other technologies in the work, which I'll comment only on briefly. We have a cardiac surgery IDE also enrolling as we speak, treating preoperative atrial fibrillation in patients undergoing open heart surgery. Suffice it to say, that's a large market. It's under-penetrated. Most importantly, all patients today are treated with radiofrequency.

You can imagine how our technology will arrive as the first PFA and have a disruptive potential to RF. We have non-cardiac applications, the first of which is to treat benign thyroid nodules, 150,000 surgeries performed every year to remove the thyroid to treat this disease. We have ample evidence to show that we can disrupt and dislocate many of those surgeries and make them non-invasive, minimally invasive, literally having the patient undergo a 30- to 45-minute procedure, go home the same day with only a Band-Aid, and preserve thyroid function. By the way, the thyroid produces hormones that control your blood pressure, your body temperature, your heart rate, and your metabolism. So, preservation of the thyroid should be a principal focus of endocrinology, and our technology allows for that. So in conclusion, this is a novel energy form.

We should be the only practitioners of this for as far as we can foresee in the future. That's a 285 patent IP moat around a very novel form of pulsed electric field energy, and that produces a very novel mechanism of action. We're well on our way to producing compelling clinical evidence with long-term follow-up, multiple IDEs, extremely large opportunistic market opportunities, including AFib, perhaps the hottest market in the med tech space, supported by an enrolled IDE, a subsequent IDE on the way, and a balance sheet aiming at $200 million cash on hand by the end of the year that provides us more than adequate resources to achieve all of the milestones that we just articulated. With that, Rick, I'll stop.

Rick Wise
Analyst, Stifel

Sounds good. That was a great, as expected, a fabulous and very clear overview. You have, as you say, in late October, the IDE data now in hand. I want to ask the question simply, just talk us through the timelines for each step of the U.S. regulatory path ahead. I'm guessing 2028 approval.

Paul LaViolette
CEO and Co-Chairman, Pulse Biosciences

Yes.

Rick Wise
Analyst, Stifel

I don't know what you're saying, but you've also talked about separately CE mark approval—

Paul LaViolette
CEO and Co-Chairman, Pulse Biosciences

Yes

Rick Wise
Analyst, Stifel

—or a little sooner. Talk us through those timelines and what your expectations are.

Paul LaViolette
CEO and Co-Chairman, Pulse Biosciences

Yes. We have commenced modular submissions for each of those pathways. The regulatory milestones are already underway. Then, of course, the seminal element for the PMA will be the clinical module, which will be fueled by the IDE. If you think about our timeline between now and Q2 of next year, it's about aggregating follow-up data from the IDE. The clinical module will be the fifth and final module to go to the FDA in housing that clinical data with a full analysis. That will go into the agency in Q3 of 2027, enabling, to your point, Rick, 2028 approval. But we expect that approval to be quite early in 2028. The approval time once submitted is six months. Of course, approval can take more or less time, principally as a function of how clean are your data and is there anything controversial.

If you have clean data and strong safety data and you've clearly met your endpoints, you really do provide the FDA with not a lot to review at that point, and that substantiates the 180-day review time and the early 2028 U.S. launch time. The CE mark has a slightly shorter timeline, because a notified body will typically require about six months' review of a slightly less arduous submission. That has also commenced, and we expect the CE mark in the second half of 2027.

Rick Wise
Analyst, Stifel

Labels for AFib have changed repeatedly over the decades. I most recently thought about paroxysmal, persistent, longstanding persistent. Is nPulse more optimally suited to one of these patient cohorts or segments?

Paul LaViolette
CEO and Co-Chairman, Pulse Biosciences

Yeah. Well, the majority of our work to date has been in paroxysmal AF. Paroxysmal AF has a more, I'd say, narrowly defined lesion set—

Rick Wise
Analyst, Stifel

Right.

Paul LaViolette
CEO and Co-Chairman, Pulse Biosciences

—of pulmonary vein isolation. To your point, the speed with which our energy is delivered, the ease with which our catheter is manipulated in the left atrium, one would argue it is actually more appropriately on target for more complex ablations. That's exactly why we're pulling the persistent IDE forward and starting it only a quarter or two after the completion of the paroxysmal. Most companies, those who have preceded us, have followed their paroxysmal approval with a persistent label expansion a year or two later. We expect to pull that in. We're going to rev up, if you will, the existing clinical sites from our paroxysmal study and get them going as early as we receive IDE approval. We'll articulate that protocol and our enrollment timeline upon receipt of approval of the IDE, which we expect in the next couple of months.

But suffice it to say, we are very enthusiastic about the ability to impact paroxysmal and persistent AF, and the majority of patients in that prevalence pool are persistent.

Rick Wise
Analyst, Stifel

I am selfishly just asking things I am curious about. I apologize. But one of the biggest surprises to me of the PFA revolution is that docs seem reluctant to throw away their RF. They want Affera, a bigger, more expensive device, because it has RF energy. Everybody is now pressured to have that. They want their mapping integrated. How do those dynamics play into the Pulse story?

Paul LaViolette
CEO and Co-Chairman, Pulse Biosciences

Well, two very good points and very different. Mapping is important, and a good ablation system should be nicely integrated into a navigation system so that the physician really can optimize placement. Suffice it to say, we have high levels of integration with existing mapping systems. We demonstrated that with the Abbott EnSite X EP system, which was used to map our cases in the first IDE. We will talk more about more diversified mapping integrations when we do our persistent IDE. To me, the concept of integrating RF with PFA, it is almost oxymoronic. We have worked for decades to try to find a way to address tissue non-thermally.

The idea of taking a relatively weak microsecond PFA energy and supplementing it by adding RF to it is somewhat antithetical. Suffice it to say, that is not a necessary consideration if you start with the right generator and if you use our nsPFA. So, you will not see RF integrated with our system, nor will you have any need to based on lesion-creating power, lesion depth, lesion consistency, the ability to use a large footprint and ablate consistently. We have all of those things organically from our one energy. We would not, I would say, default to a dual energy, which I just want to emphasize is only used to offset weaknesses of first-generation PFA.

Rick Wise
Analyst, Stifel

Got it. A question that often comes up when I am asked or people share observations about Pulse Biosciences with me, is they ask about, "Yes, but how will they bundle?", which is in the context of a broader EP business. Talk about the company's ability to function as an independent standalone. It is not fair to say single line, but narrowly focused, even with a brilliant technology.

How do you manage that dynamic as you think about becoming commercial?

Paul LaViolette
CEO and Co-Chairman, Pulse Biosciences

Right. Well, I think the evidence over the last two years, especially with Boston Scientific's launch, a company with which I have a significant history, their launch into EP was essentially de novo. They had no history in EP. They had no entrenched mapping position. What they did was bring a next-generation ablation energy, and it disrupted the market and moved them to a majority market share position and moved the combination of Abbott and J&J to below 20% market share. If ever there was evidence of the ability to use a next-generation ablation energy to change market share from a non-incumbent position, we have prima facie evidence in the last two years. However, Pulse is also not of the scale of Boston Scientific, and so we appreciate the fact that the EP market is a complex ecosystem. We have to be integrated with mapping.

Fortunately, because new companies such as Boston Scientific have moved in and forced others to map them, most of the mapping systems today are open architecture. So the combination of an open architecture mapping environment and a disruptive energy is very powerful. However, our principal strategy is to prepare for a strategic partnership. Bundling concepts and other things can be mitigated by a go-to-market strategy that is partnership-focused. We are building our company with the ability to go either way, but it is such a compelling market and such compelling technology, we expect strategic partners to be very focused on working with us to bring this technology to market under one of their brands.

Rick Wise
Analyst, Stifel

Excellent. On that note, that sounds like a wonderful place to stop. I have got three pages of additional questions. The next time, I think we have to schedule a double session for Pulse. Thank you so much, Paul.

Paul LaViolette
CEO and Co-Chairman, Pulse Biosciences

It is a deal.

Rick Wise
Analyst, Stifel

Appreciate it.

Paul LaViolette
CEO and Co-Chairman, Pulse Biosciences

Thank you. My pleasure.